Drug Profile
Depoxythilone - Beijing Biostar Technologies
Alternative Names: UTD-1; UTD-2; Utidelone; Utidelone - Beijing Biostar TechnologiesLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Beijing Biostar Technologies; BioStar Pharmaceuticals
- Developer Beijing Biostar Technologies; BioStar Pharmaceuticals; Henan Cancer Hospital
- Class Antineoplastics; Epothilones
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III Non-small cell lung cancer
- Phase II Colorectal cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 21 Mar 2024 Depoxythilone - Beijing Biostar Technologies receives Orphan Drug status for Gastric cancer in USA
- 15 Jun 2023 US FDA approves IND application for depoxythilone (Utidelone) in Non-small cell lung cancer
- 15 Jun 2023 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer released by BioStar Pharmaceuticals